Recent research presented at a scientific conference in San Francisco highlights the potential of a drug called ensitrelvir, developed by the Japanese pharmaceutical company Shionogi, to prevent COVID-19 infections. Currently approved in Japan as a treatment for COVID-19, ensitrelvir has shown promise in reducing both hospitalizations and the duration of symptoms in individuals at higher risk.
The study involved over 2,300 participants aged 12 and older who lived with someone testing positive for SARS-CoV-2. These individuals were randomly assigned to receive either ensitrelvir or a placebo for five days, starting within three days after their housemate exhibited symptoms. Results indicated that only about 3% of those taking ensitrelvir contracted COVID-19, compared to 9% in the placebo group, suggesting a 67% reduction in infection risk.
Dr. Frederick Hayden, a professor emeritus at the University of Virginia, emphasized the significance of these findings, stating that this is the first documented instance of an oral antiviral successfully preventing COVID-19 in high-risk environments such as households. The study specifically noted a 76% reduction in risk for older adults and immunocompromised individuals, underscoring the importance of preventing infection to avoid complications like Long COVID.
Ensitrelvir functions by inhibiting the virus's ability to replicate, making it effective both as a preventive measure and a treatment. The U.S. Food and Drug Administration is currently considering fast-track approval for ensitrelvir as a preventative option based on these findings, although the study has yet to undergo peer review. This research could represent a meaningful step towards enhancing public health measures against COVID-19.